Last updated: January 18, 2025
Sponsor: Tanta University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Dementia
Treatment
Salivary Alpha-amylase
Clinical Study ID
NCT06242275
36264PR462/12/23
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 65 years.
Both sexes.
American Society of Anesthesiologists (ASA) physical status III.
Undergoing lower extremity vascular surgery under general anesthesia.
Exclusion
Exclusion Criteria:
Patients who used any medication that could affect salivary glands (such asantihypertensive, antidepressants or antipsychotic drugs).
Inability to communicate.
History of psychiatric diseases or previous stroke
Previous history of pod.
Those with smoking and drinking habits.
Pregnant female.
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Salivary Alpha-amylase
Phase:
Study Start date:
February 10, 2024
Estimated Completion Date:
April 12, 2025
Study Description
Connect with a study center
Tanta University
Tanta, El-Gharbia 31527
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.